https://scholars.lib.ntu.edu.tw/handle/123456789/504038
標題: | Pharmacogenomic variations in treatment protocols for childhood acute lymphoblastic leukemia | 作者: | YUNG-LI YANG Lin D.-T. Chang S.-K. Lin S.-R. SHU-WHA LIN Chiou R.-J. Yen C.-T. Lin K.-H. SHIANN-TANG JOU MENG-YAO LU HSIU-HAO CHANG Chang W.-H. Lin K.-S. CHUNG-YI HU |
公開日期: | 2010 | 卷: | 54 | 期: | 2 | 起(迄)頁: | 206_211 | 來源出版物: | Pediatric Blood and Cancer | 摘要: | Objectives. This retrospective study evaluates the role of pharmacogenomic determinants in the treatment of childhood acute lymphoblastic leukemia (ALL) in the Taiwanese population. Methods. A total of 105 childhood ALL patients received combined chemotherapy of different intensities based on risk-directed Taiwan Pediatric Oncology Group (TPOG)-ALL-93 protocols. Seventeen genetic polymorphisms in 13 pharmacogenomic targets were analyzed by PCR-based restriction fragment length polymorphism (RFLP) and sequence-specific oligonucleotide (SSO) probe hybridization. Pharmacogenomic polymorphisms were correlated with event-free survival (EFS) of patients, with confounding effects adjusted by multivariate regression. Results. Three polymorphic alleles in the multi-drug resistance 1 (MDR1) ABCB1 gene, and homozygotic MDR1 2677GG, 3435CC, and 2677G-3435C genotypes were highly associated with a significant reduction in EFS in those patients treated by the standard risk (SR) protocol (TPOG-ALL-93-SR). The hazard ratios were 6.8 (p=0.01), 21.7 (p=0.009), and 6.8 (p=0.01), respectively. Conclusions. Independent pharmacogenomic determinants associated with treatment outcome were identified in subsets of Taiwanese ALL patients. ? 2009 Wiley-Liss, Inc. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/504038 | ISSN: | 1545-5009 | DOI: | 10.1002/pbc.22292 | SDG/關鍵字: | multidrug resistance protein 1; oligonucleotide; acute lymphoblastic leukemia; allele; article; cancer risk; cancer survival; child; childhood leukemia; controlled study; female; genetic polymorphism; genotype; homozygote; human; infant; major clinical study; male; outcome assessment; pharmacogenomics; polymerase chain reaction; preschool child; priority journal; prognosis; restriction fragment length polymorphism; school child; Taiwan; Antineoplastic Combined Chemotherapy Protocols; Asian Continental Ancestry Group; Child; Child, Preschool; Drug Resistance; Female; Humans; Infant; Infant, Newborn; Male; Multivariate Analysis; P-Glycoprotein; Pharmacogenetics; Polymorphism, Genetic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taiwan |
顯示於: | 醫學檢驗暨生物技術學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。